| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 坚定自主创新，致力于服务医疗事业，迪瑞医疗科技股份有限公司作为华润产业基金控股的高新技术企业，1992年创办于中国长春，是国内体外诊断行业领先企业之一、国家技术创新示范企业。公司专注于高品质医疗检验产品的研发、生产、营销与服务，竭诚为守护生命健康贡献智慧与力量，现拥有尿液分析、生化分析、化学发光免疫分析、妇科分泌物分析、血细胞分析、凝血分析、分子诊断分析、整体化实验室8大产品线，覆盖医院检验科80%以上检测项目，能够为医学实验室提供整体解决方案。每年持续投入销售收入的10%-15%到产品与技术的研发中，已构建具有国际水平的医疗检验产品研发平台，其中全自动尿液分析系统、尿液干化学分析质控物、妇科分泌物分析系统等产品技术达到行业领先水平。30年行业深耕，迪瑞产品获得了国内14000多家医疗机构及全球120多个国家和地区用户的信赖。其中全自动尿液分析仪在国内三级市场的市场占有率达到28%以上，尿液类产品在部分欧洲国家市场占有率位列第一。 在“十四五”发展战略的引领下，公司已建成国内长春、深圳两大研究院，长春、北京、武汉三大运营中心、26个省级办事处及国际7家境外子公司，业务覆盖120多个国家和地区。全体迪瑞人将积极践行企业使命，始终牢记企业愿景，向世界展示中国智造的魅力。 | ||||||||||||||||||||||||
| Main Business | 医疗检验仪器及配套试纸试剂的研发、生产、营销与服务。 | ||||||||||||||||||||||||
| Legal Representative | 王学敏 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 安国柱 | ||||||||||||||||||||||||
| Solicitors | 北京市君泽君律师事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0431-81931002 | ||||||||||||||||||||||||
| Fax No | 0431-81931002 | ||||||||||||||||||||||||
| Website | www.dirui.com.cn | ||||||||||||||||||||||||
| zqb@dirui.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/09/2014 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.010 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.500 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.424 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 6.559B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |